Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Theriva Biologics, Inc. is a clinical-stage biotechnology company focused on the development of therapeutics for cancer and related conditions, with a primary emphasis on oncolytic virus-based therapies. The company operates within the biotechnology and pharmaceutical research industries and does not currently generate commercial product revenue. Its core strategy centers on advancing proprietary drug candidates through clinical development to address areas of high unmet medical need, particularly in oncology.
The company’s principal programs include VCN-01, an oncolytic adenovirus designed to selectively replicate within tumors and modify the tumor microenvironment, and SYN-004 (ribaxamase), an orally administered enzyme intended to degrade certain intravenous antibiotics in the gastrointestinal tract to reduce microbiome disruption. Theriva Biologics traces its origins to 2001 and previously operated as Synthetic Biologics, Inc. before rebranding to its current name in 2021 to reflect a strategic shift toward oncology-focused biologics development.
Business Operations
Theriva Biologics conducts its operations primarily through research and development activities, with expenditures focused on preclinical studies, clinical trials, regulatory planning, and intellectual property management. The company’s operating model relies heavily on outsourcing clinical trial execution and manufacturing to third-party contract research and manufacturing organizations rather than maintaining large internal facilities.
The company’s business is organized around its development pipeline rather than commercial segments, with VCN-01 representing its lead oncology asset and SYN-004 (ribaxamase) constituting a separate gastrointestinal protection program. Theriva does not report meaningful domestic or international sales and instead finances operations through equity offerings, licensing arrangements, and research collaborations.
Strategic Position & Investments
Theriva Biologics’ strategic direction is centered on advancing VCN-01 through mid- to late-stage clinical trials, particularly in combination with standard-of-care therapies for pancreatic cancer. The company positions itself within the niche of tumor-modifying oncolytic viruses, seeking differentiation through its platform’s ability to both lyse cancer cells and enhance drug delivery within dense tumor tissue.
Historically, the company has pursued strategic partnerships and licensing arrangements to support development and regional commercialization, including rights related to VCN-01 originating from academic and international research institutions. No major acquisitions or controlling investments in unrelated businesses have been disclosed in recent public filings, and the company remains focused on organic pipeline advancement rather than portfolio diversification.
Geographic Footprint
Theriva Biologics is headquartered in the United States, with corporate functions based in Massachusetts. Its operational footprint is primarily virtual, relying on third-party partners across North America and Europe for clinical trials, manufacturing, and regulatory support.
Clinical development activities extend internationally, as patient enrollment and research collaborations have included sites in Europe and other regions depending on trial design. Despite this international clinical presence, the company does not maintain significant owned facilities or regional subsidiaries outside the United States.
Leadership & Governance
Theriva Biologics is led by an executive team with experience in biotechnology development, capital markets, and clinical strategy. The leadership emphasizes disciplined capital allocation, partnering, and focused advancement of a limited number of high-impact assets rather than broad pipeline expansion.
Key executives include:
- Steven A. Shallcross – President and Chief Executive Officer
- Eric M. Sorscher – Chief Financial Officer
- Sergio Santillana – Chief Medical Officer
The company is governed by a board of directors that includes members with backgrounds in biotechnology, finance, and corporate governance. Leadership information beyond these roles is data inconclusive based on available public sources due to limited recent disclosures.